Se­lec­ta lets go 25% of work­force, paus­es PhI/II gene ther­a­py tri­al

Se­lec­ta Bio­sciences, which is de­vel­op­ing im­munother­a­pies and gene ther­a­pies, is cut­ting its work­force by 25% and paus­ing de­vel­op­ment of its whol­ly-owned gene ther­a­py pro­grams. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER